Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans

Overview

Journal Infect Chemother

Specialty Infectious Diseases

Date 2021 Aug 18

PMID 34405598

Citations 7

Affiliations

Soon will be listed here.

Abstract

Since the establishment of the Committee for Clinical Guidelines for the Diagnosis and Treatment of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) by the Korean Society for AIDS in 2010, clinical guidelines have been prepared in 2011, 2013, 2015, and 2018. As new research findings on the epidemiology, diagnosis, and treatment of AIDS have been published in and outside of Korea along with the development and introduction of new antiretroviral medications, a need has arisen to revise the clinical guidelines by analyzing such new data. The clinical guidelines address the initial evaluation of patients diagnosed with HIV/AIDS, follow-up tests, appropriate timing of medication, appropriate antiretroviral medications, treatment strategies for patients who have concurrent infections with hepatitis B or C virus, recommendations for resistance testing, treatment for patients with HIV and tuberculosis coinfections, and treatment in pregnant women. Through these clinical guidelines, the Korean Society for AIDS and the Committee for Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS contributes to overcoming AIDS by delivering latest data and treatment strategies to healthcare professionals who treat AIDS in the clinic.

Citing Articles

Epidemiological Characteristics of HIV-Infected Individuals by the Registration for Special Exempted Calculation: A Nationwide Cohort Study.

Choi Y, Ahn K, Kim S, Choi B, Choi J, Kim J Infect Chemother. 2025; 56(4):510-521.

PMID: 39762927 PMC: 11704859. DOI: 10.3947/ic.2024.0085.

HIV Late Presenters in Asia: Management and Public Health Challenges.

Wong C, Wei L, Kim Y AIDS Res Treat. 2023; 2023:9488051.

PMID: 37351535 PMC: 10284655. DOI: 10.1155/2023/9488051.

Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study.

Srisopa S, Kornjirakasemsan A, Treebupachatsakul P, Sonthisombat P Infect Chemother. 2023; 55(2):226-236.

PMID: 37272235 PMC: 10323539. DOI: 10.3947/ic.2023.0001.

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1.

Shin S, Cho J, Lee E, Kim Y, Jung S Infect Chemother. 2023; 55(3):337-345.

PMID: 37272234 PMC: 10551717. DOI: 10.3947/ic.2022.0176.

Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020.

Oh S, Bang J, Park S, Lee E Infect Chemother. 2023; 55(3):328-336.

PMID: 37272233 PMC: 10551708. DOI: 10.3947/ic.2022.0150.

References

Matthews G, Seaberg E, Dore G, Bowden S, Lewin S, Sasadeusz J . Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009; 23(13):1707-15. PMC: 2918388. DOI: 10.1097/QAD.0b013e32832b43f2. View

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390(10107):2063-2072. DOI: 10.1016/S0140-6736(17)32299-7. View

Borroto-Esoda K, Waters J, Bae A, Harris J, Hinkle J, Quinn J . Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses. 2007; 23(8):988-95. DOI: 10.1089/aid.2006.0310. View

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View

Cahn P, Pozniak A, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva J . Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382(9893):700-8. DOI: 10.1016/S0140-6736(13)61221-0. View

Del Romero J, Baza M, Rio I, Jeronimo A, Vera M, Hernando V . Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study. Medicine (Baltimore). 2016; 95(30):e4398. PMC: 5265870. DOI: 10.1097/MD.0000000000004398. View

Kaplan J, Masur H, Holmes K . Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002; 51(RR-8):1-52. View

Townsend C, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H . Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014; 28(7):1049-57. DOI: 10.1097/QAD.0000000000000212. View

Read P, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y . When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?. AIDS. 2012; 26(9):1095-103. DOI: 10.1097/QAD.0b013e3283536a6c. View

10.

Hogg R, Yip B, Chan K, Wood E, Craib K, OShaughnessy M . Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001; 286(20):2568-77. DOI: 10.1001/jama.286.20.2568. View

11.

Boulware D, Meya D, Muzoora C, Rolfes M, Hullsiek K, Musubire A . Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014; 370(26):2487-98. PMC: 4127879. DOI: 10.1056/NEJMoa1312884. View

12.

Becquet R, Ekouevi D, Arrive E, Stringer J, Meda N, Chaix M . Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis. 2009; 49(12):1936-45. PMC: 3309024. DOI: 10.1086/648446. View

13.

Wohl D, Cohen C, Gallant J, Mills A, Sax P, DeJesus E . A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013; 65(3):e118-20. DOI: 10.1097/QAI.0000000000000057. View

14.

Ragni M, Nalesnik M, Schillo R, Dang Q . Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia. 2009; 15(2):552-8. PMC: 2722242. DOI: 10.1111/j.1365-2516.2008.01935.x. View

15.

Aberg J, Kaplan J, Libman H, Emmanuel P, Anderson J, Stone V . Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(5):651-81. DOI: 10.1086/605292. View

16.

van Lunzen J, Antinori A, Cohen C, Arribas J, Wohl D, Rieger A . Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2015; 30(2):251-9. DOI: 10.1097/QAD.0000000000000911. View

17.

. ACOG Committee Opinion No. 762: Prepregnancy Counseling. Obstet Gynecol. 2018; 133(1):e78-e89. DOI: 10.1097/AOG.0000000000003013. View

18.

Peters M, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart C . Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006; 44(5):1110-6. PMC: 4114764. DOI: 10.1002/hep.21388. View

19.

Labhardt N, Ringera I, Lejone T, Klimkait T, Muhairwe J, Amstutz A . Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial. JAMA. 2018; 319(11):1103-1112. PMC: 5885884. DOI: 10.1001/jama.2018.1818. View

20.

Clumeck N, Molina J, Henry K, Gathe J, Rockstroh J, DeJesus E . A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013; 65(3):e121-4. DOI: 10.1097/QAI.0000000000000089. View